Chugai Pharmaceutical Co., Ltd.
4519
Classifica tra le azioni
#346
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Prezzo delle azioni
$42.53
Capitalizzazione di mercato
$69.98B
Variazione (1 giorno)
1.37%
Variazione (1 anno)
-14.40%
Paese
JP
Scambia Chugai Pharmaceutical Co., Ltd. (4519)
Categoria
Healthcare
Storico del prezzo dell'azione per Chugai Pharmaceutical Co., Ltd. (4519)
Prezzo di chiusura più alto: $38.86 il 2026-10-01
Prezzo di chiusura più basso: $51.75 il 2000-11-01
Prezzo di chiusura più basso: $51.75 il 2000-11-01
Storico del prezzo dell'azione di Chugai Pharmaceutical Co., Ltd. dal 2000 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -7.35% |
| 2025 | 24.85% |
| 2024 | 17.22% |
| 2023 | 54.46% |
| 2022 | -26.90% |
| 2021 | -29.65% |
| 2020 | 549.58% |
| 2019 | -29.61% |
| 2018 | 118.94% |
| 2017 | 21.69% |
| 2016 | -66.07% |
| 2015 | 245.37% |
| 2014 | 26.29% |
| 2013 | -97.98% |
| 2012 | 161.03% |
| 2011 | -12.65% |
| 2010 | -8.22% |
| 2009 | 13.93% |
| 2008 | 6.97% |
| 2007 | -20.27% |
| 2006 | -7.51% |
| 2005 | 47.49% |
| 2004 | 2.63% |
| 2003 | 84.70% |
| 2002 | -39.16% |
| 2001 | -23.39% |
| 2000 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $1.27K | 59.16% |
US
|
|
| $257.61 | 34.26% |
US
|
|
| $284.48 | 22.94% |
US
|
|
| $149.84 | 71.01% |
US
|
|
| $482.98 | 31.13% |
CH
|
